The rationale and study design of two phase II trials examining the efects of BI 685,509,a soluble guanylyl cyclase activator, on clinicallysignifcant portal hypertension in patientswith compensated cirrhosis

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Reiberger T, Berzigotti A, Trebicka J, Ertle J, Gashaw I, Swallow R, Tomisser A.

Journal title: Trials

Journal number: Apr 24;24(1)

Journal publisher: Springer Nature

Published year: 2023

Published pages: 293

DOI identifier: 10.1186/s13063-023-07291-3